SEARCH

SEARCH BY CITATION

References

  • 1
    Terasaki PI. Deduction of the fraction of immunologic and non-immunologic failure in cadaver donor transplants. Clin Transpl 2003; 449452.
  • 2
    Opelz G. Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. Lancet 2005; 365: 15701576.
  • 3
    Zachary AA, Montgomery RA, Jordan SC, Reinsmoen NL, Claas FH, Reed EF. 14th International HLA and Immunogenetics Workshop: Report on understanding antibodies in transplantation. Tissue Antigens 2007; 69 (Suppl 1) 160173.
  • 4
    McKenna RM, Takemoto SK, Terasaki PI. Anti-HLA antibodies after solid organ transplantation. Transplantation 2000; 69: 319326.
  • 5
    Terasaki P, Lachmann N, Cai J. Summary of the effect of de novo HLA antibodies on chronic kidney graft failure. Clin Transpl 2006; 455462.
  • 6
    Zhang X, Reed EF. Effect of antibodies on endothelium. Am J Transplant 2009; 9: 24592465.
  • 7
    Nath DS, Basha HI, Mohanakumar T. Antihuman leukocyte antigen antibody-induced autoimmunity: Role in chronic rejection. Curr Opin Organ Transplant 2010; 15: 1620.
  • 8
    Glotz D, Lucchiari N, Pegaz-Fiornet B, Suberbielle-Boissel C. Endothelial cells as targets of allograft rejection. Transplantation 2006; 82 (Suppl 1): 1921.
  • 9
    Zhang Q, Reed EF. Non-MHC antigenic targets of the humoral immune response in transplantation. Curr Opin Immunol 2010; 22: 682688.
  • 10
    Sumitran-Holgersson S. Beyond ABO and human histocompatibility antigen: Other histocompatibility antigens with a role in transplantation. Curr Opin Organ Transplant 2008; 13: 425429.
  • 11
    Tinckam KJ, Chandraker A. Mechanisms and role of HLA and non-HLA alloantibodies. Clin J Am Soc Nephrol 2006; 1: 404414.
  • 12
    Regele H. Non-HLA antibodies in kidney allograft rejection: Convincing concept in need of further evidence. Kidney Int 2011; 79: 583586.
  • 13
    Fredrich R, Toyoda M, Czer LS, et al. The clinical significance of antibodies to human vascular endothelial cells after cardiac transplantation. Transplantation 1999; 67: 385391.
  • 14
    Faulk WP, Rose M, Meroni PL, et al. Antibodies to endothelial cells identify myocardial damage and predict development of coronary artery disease in patients with transplanted hearts. Hum Immunol 1999; 60: 826832.
  • 15
    Sumitran-Karuppan S, Tyden G, Reinholt F, Berg U, Moller E. Hyperacute rejections of two consecutive renal allografts and early loss of the third transplant caused by non-HLA antibodies specific for endothelial cells. Transpl Immunol 1997; 5: 321327.
  • 16
    Nath DS, Ilias Basha H, Tiriveedhi V, et al. Characterization of immune responses to cardiac self-antigens myosin and vimentin in human cardiac allograft recipients with antibody-mediated rejection and cardiac allograft vasculopathy. J Heart Lung Transplant 2010; 29: 12771285.
  • 17
    Carter V, Shenton BK, Jaques B, et al. Vimentin antibodies: A non-HLA antibody as a potential risk factor in renal transplantation. Transplant Proc 2005; 37: 654657.
  • 18
    Jurcevic S, Ainsworth ME, Pomerance A, et al. Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation. Transplantation 2001; 71: 886892.
  • 19
    Morgun A, Shulzhenko N, Unterkircher CS, et al. Pre- and post-transplant anti-myosin and anti-heat shock protein antibodies and cardiac transplant outcome. J Heart Lung Transplant 2004; 23: 204209.
  • 20
    Li Y, Heuser JS, Cunningham LC, Kosanke SD, Cunningham MW. Mimicry and antibody-mediated cell signaling in autoimmune myocarditis. J Immunol 2006; 177: 82348240.
  • 21
    Reinsmoen NL, Lai CH, Heidecke H, et al. Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients. Transplantation 2010; 90: 14731477.
  • 22
    Dragun D, Muller DN, Brasen JH, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005; 352: 558569.
  • 23
    Gasc JM, Shanmugam S, Sibony M, Corvol P. Tissue-specific expression of type 1 angiotensin II receptor subtypes. An in situ hybridization study. Hypertension 1994; 24: 531537.
  • 24
    Crowley SD, Gurley SB, Herrera MJ, et al. Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci USA 2006; 103: 1798517990.
  • 25
    de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000; 52: 415472.
  • 26
    Gurley SB, Riquier-Brison AD, Schnermann J, et al. AT1A angiotensin receptors in the renal proximal tubule regulate blood pressure. Cell Metab 2011; 13: 469475.
  • 27
    Dzau VJ. Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: A unifying hypothesis. Hypertension 2001; 37: 10471052.
  • 28
    Mehta PK, Griendling KK. Angiotensin II cell signaling: Physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007; 292: C82C97.
  • 29
    Deshayes F, Nahmias C. Angiotensin receptors: A new role in cancer? Trends Endocrinol Metab 2005; 16: 293299.
  • 30
    Zou LX, Imig JD, von Thun AM, Hymel A, Ono H, Navar LG. Receptor-mediated intrarenal angiotensin II augmentation in angiotensin II-infused rats. Hypertension 1996; 28: 669677.
  • 31
    Coffman TM, Crowley SD. Kidney in hypertension: Guyton redux. Hypertension 2008; 51: 811816.
  • 32
    Kon V, Jabs K. Angiotensin in atherosclerosis. Curr Opin Nephrol Hypertens 2004; 13: 291297.
  • 33
    Nobuhiko A, Suganuma E, Babaev VR, et al. Angiotensin II amplifies macrophage-driven atherosclerosis. Arterioscler Thromb Vasc Biol 2004; 24: 21432148.
  • 34
    Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteria—An addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708714.
  • 35
    Mao Q, Terasaki PI, Cai J, et al. Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five-year longitudinal study. Am J Transplant 2007; 7: 864871.
  • 36
    Mizutani K, Terasaki P, Rosen A, et al. Serial ten-year follow-up of HLA and MICA antibody production prior to kidney graft failure. Am J Transplant 2005; 5: 22652272.
  • 37
    Piazza A, Poggi E, Ozzella G, et al. Post-transplant donor-specific antibody production and graft outcome in kidney transplantation: Results of sixteen-year monitoring by flow cytometry. Clin Transpl 2006; 323336.
  • 38
    Mizutani K, Terasaki P, Hamdani E, et al. The importance of anti-HLA-specific antibody strength in monitoring kidney transplant patients. Am J Transplant 2007; 7: 10271031.
  • 39
    Hiemann NE, Meyer R, Wellnhofer E, Schoenemann C, et al. Non-HLA antibodies targeting vascular receptors enhance alloimmune response and microvasculopathy after heart transplantation. Transplantation 2012; 94: 919924.
  • 40
    Siekierka-Harreis M, Kuhr N, Willers R, et al. Impact of genetic polymorphisms of the renin–angiotensin system and of non-genetic factors on kidney transplant function—A single-center experience. Clin Transplant 2009; 23: 606615.
  • 41
    Yamani MH, Cook DJ, Rodriguez ER, et al. Increased expression of angiotensin II type 1 receptor (AGTR1) in heart transplant recipients with recurrent rejection. J Heart Lung Transplant 2006; 25: 12831289.
  • 42
    Xu ZG, Lanting L, Vaziri ND, et al. Upregulation of angiotensin II type 1 receptor, inflammatory mediators, and enzymes of arachidonate metabolism in obese Zucker rat kidney: Reversal by angiotensin II type 1 receptor blockade. Circulation 2005; 111: 19621969.
  • 43
    Zhan Y, Brown C, Maynard E, et al. Ets-1 is a critical regulator of Ang II-mediated vascular inflammation and remodeling. J Clin Invest 2005; 115: 25082516.
  • 44
    Pearse DD, Tian RX, Nigro J, Iorgulescu JB, Puzis L, Jaimes EA. Angiotensin II increases the expression of the transcription factor ETS-1 in mesangial cells. Am J Physiol Renal Physiol 2008; 294: F1094F1100.
  • 45
    Dragun D, Catar RA, Naether M, Phillipe A, Eisenreich A, Rauch U. Non-HLA antibodies simultaneously targeting endothelial AT1- and ETA receptors induce proliferation and coagulation via Ets-1 and TF activation [abstract]. Am J Transplant 2011; 11 (Suppl 2): 69.